Skip to main content
SpringerLink
Log in

Immune-Mediated Drug-Induced Liver Injury

  • Chapter
  • First Online:
Liver Immunology

Abstract

Drug-induced liver injury (DILI) has previously been classified into immunologic or metabolic idiosyncracy. Metabolic idiosyncrasy implies that a subject developing adverse reaction metabolises the drug in a different way than the most individuals or lacks adequate protective mechanisms to neutralise reactive metabolites formed. An immunologic idiosyncrasy implies that the susceptible individual has an immune system that would more readily recognise the formed neoantigens. Alternatively, immune system through cytokines and chemokines may modulate the degree of hepatic inflammation secondary to toxic injury. However, this classification derived from clinical observations such as latent period, presence or absence of manifestations attributable to hypersensitivity and pattern of response to re-challenge is too simplistic to be accurate. Increasingly, it is evident that the development of idiosyncratic DILI is a multistep process involving both metabolic and immunologic factors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol. 2010;146(12):1373–9.

    Article  PubMed  Google Scholar 

  2. Walsh SA, Creamer D. Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol. 2011;36:6–11.

    Article  PubMed  CAS  Google Scholar 

  3. Daubner B, Groux-Keller M, Hausmann OV, Kawabata T, Naisbitt DJ, Park BK, Wendland T, et al. Multiple drug hypersensitivity: normal Treg cell function but enhanced in vivo activation of drug-specific T cells. Allergy. 2012;67:58–66.

    Article  PubMed  CAS  Google Scholar 

  4. Larrey D, Berson A, Habersetzer F, Tinel M, Castot A, Babany G, Letteron P, et al. Role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology. 1989;10:168–73.

    Article  PubMed  CAS  Google Scholar 

  5. Zimmerman HJ. Drug-induced liver disease. In: Sciff ER, Sorrell MF, Maddrey WC, editors. Schiff’s diseases of the liver. 8th ed. Philadelphia: Lippincott-Raven; 1999. p. 973–1064.

    Google Scholar 

  6. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis. 2002;6:755–74.

    Article  PubMed  Google Scholar 

  7. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol. 1999;12:387–95.

    Article  PubMed  CAS  Google Scholar 

  8. Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513–39.

    Article  PubMed  CAS  Google Scholar 

  9. Ibanez L, Perez E, Vidal X, Laporte JR. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol. 2002;37:592–600.

    Article  PubMed  Google Scholar 

  10. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology. 2005;129:512–21.

    PubMed  Google Scholar 

  11. Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25:1411–21.

    Article  PubMed  Google Scholar 

  12. Björnsson E, Nordlinder H, Olsson R. Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J Hepatol. 2006;44:791–7.

    Article  PubMed  Google Scholar 

  13. Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M. Drug-induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology. 2011;54:1344–50.

    Article  PubMed  CAS  Google Scholar 

  14. Lampinen M, Rönnblom A, Amin K, Kristjansson G, Rorsman F, Sangfelt P, Säfsten B, et al. Eosinophil granulocytes are activated during the remission phase of ulcerative colitis. Gut. 2005;54:1714–20.

    Article  PubMed  CAS  Google Scholar 

  15. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29:364–72.

    Article  PubMed  Google Scholar 

  16. Kleiner D, Chalasani N, Conjeevaram HS, et al. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-induced Liver Injury Network. Gastroenterology. 2007;132:A773.

    Google Scholar 

  17. Aithal GP. Hepatotoxicity related to antirheumatic drugs. Nat Rev Rheumatol. 2011;7:139–50.

    Article  PubMed  CAS  Google Scholar 

  18. Andrews E, Armstrong M, Tugwood J, Swan D, Glaves P, Pirmohamed M, Aithal GP, et al. A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology. 2010;51:1656–64.

    Article  PubMed  CAS  Google Scholar 

  19. Park BK, Laverty H, Srivastava A, Antoine DJ, Naisbitt D, Williams DP. Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chem Biol Interact. 2011;192(1–2):30–6.

    Article  PubMed  CAS  Google Scholar 

  20. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis. 2007;11:563–75.

    Article  PubMed  Google Scholar 

  21. Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JB, Alexander G, Kenna JG, et al. Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004;39:1430–40.

    Article  PubMed  CAS  Google Scholar 

  22. Elsheikh A, Lavergne SN, Castrejon JL, Farrell J, Wang H, Sathish J, Pichler WJ, et al. Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism. J Immunol. 2010;185:6448–60.

    Article  PubMed  CAS  Google Scholar 

  23. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe’er I, Floratos A, Daly MJ, et al.; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009;41:816–9.

  24. Monshi M, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, Alfirevic A, et al. HLA-B*57:01-restricted activation of drug-specific T-cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology. 2013;57(2):727–39.

    Article  PubMed  CAS  Google Scholar 

  25. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8:186–95.

    Article  PubMed  CAS  Google Scholar 

  26. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol. 2010;53:1049–53.

    Article  PubMed  CAS  Google Scholar 

  27. Kelly BD, Heneghan MA, Bennani F, Connolly CE, O’Gorman TA. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells. Am J Gastroenterol. 1998;93:819–21.

    PubMed  CAS  Google Scholar 

  28. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.

    Article  PubMed  CAS  Google Scholar 

  29. Barker RN, Erwig L, Pearce WP, Devine A, Rees AJ. Differential effects of necrotic or apoptotic cell uptake on antigen presentation by macrophages. Pathobiology. 1999;67:302–5.

    Article  PubMed  CAS  Google Scholar 

  30. Aithal GP. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert Opin Drug Saf. 2004;3:519–23.

    Article  PubMed  CAS  Google Scholar 

  31. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol. 2001;13:114–9.

    Article  PubMed  CAS  Google Scholar 

  32. Matzinger P. An innate sense of danger. Semin Immunol. 1998;10:399–415.

    Article  PubMed  CAS  Google Scholar 

  33. Shaw PJ, Ganey PE, Roth RA. Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci. 2010;118:7–18.

    Article  PubMed  CAS  Google Scholar 

  34. Lavergne SN, Wang H, Callan HE, Park BK, Naisbitt DJ. “Danger” conditions increase sulfamethoxazole-protein adduct formation in human antigen-presenting cells. J Pharmacol Exp Ther. 2009;331:372–81.

    Article  PubMed  CAS  Google Scholar 

  35. Wang JY, Liu CH, Hu FC, Chang HC, Liu JL, Chen JM, Yu CJ, et al. Risk factors of hepatitis during anti-tuberculous treatment and implications of hepatitis virus load. J Infect. 2011;62:448–55.

    Article  PubMed  Google Scholar 

  36. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, Pitchenik AE. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871–6.

    Article  PubMed  CAS  Google Scholar 

  37. Dworkin MS, Adams MR, Cohn DL, Davidson AJ, Buskin S, Horwitch C, Morse A, et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. J Acquir Immune Defic Syndr. 2005;39:464–70.

    Article  PubMed  CAS  Google Scholar 

  38. You Q, Cheng L, Reilly TP, Wegmann D, Ju C. Role of neutrophils in a mouse model of halothane-induced liver injury. Hepatology. 2006;44:1421–31.

    Article  PubMed  CAS  Google Scholar 

  39. Cheng L, You Q, Yin H, Holt MP, Ju C. Involvement of natural killer T cells in halothane-induced liver injury in mice. Biochem Pharmacol. 2010;80(2):255–61.

    Article  PubMed  CAS  Google Scholar 

  40. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, et al. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012;22(11):784–95.

    Article  PubMed  CAS  Google Scholar 

  41. Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand. 2008;118:281–90.

    Article  PubMed  Google Scholar 

  42. Björnsson E, Olsson R, Remotti H. Norfloxacin-induced eosinophilic necrotizing granulomatous hepatitis. Am J Gastroenterol. 2000;95:3662–4.

    Article  PubMed  Google Scholar 

  43. Won JH, Kim MJ, Kim BM, Ji H, Chung JJ, Yoo HS, Lee JT, et al. Focal eosinophilic infiltration of the liver: a mimick of hepatic metastasis. Abdom Imaging. 1999;24:369–72.

    Article  PubMed  CAS  Google Scholar 

  44. Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis. Dig Dis Sci. 2007;52:2433–7.

    Article  PubMed  CAS  Google Scholar 

  45. Suzuki A, Brunt EM, Kleiner DE, Miquel R, Smyrk TC, Andrade RJ, Isabel Lucena M, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis vs. drug-induced liver injury. Hepatology. 2011;54(3):931–9.

    Article  PubMed  Google Scholar 

  46. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, Bittencourt PL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169–76.

    Article  PubMed  Google Scholar 

  47. Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988;8:599–606.

    Article  PubMed  CAS  Google Scholar 

  48. Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci. 2011;56:958–76.

    Article  PubMed  CAS  Google Scholar 

  49. Siegmund W, Franke G, Biebler KE, Donner I, Kallwellis R, Kairies M, Scherber A, et al. The influence of the acetylator phenotype for the clinical use of dihydralazine. Int J Clin Pharmacol Ther Toxicol. 1985;23 Suppl 1:S74–8.

    PubMed  Google Scholar 

  50. Bourdi M, Tinel M, Beaune PH, Pessayre D. Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol Pharmacol. 1994;45:1287–95.

    PubMed  CAS  Google Scholar 

  51. Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf. 2000;23:333–49.

    Article  PubMed  CAS  Google Scholar 

  52. Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15:921–4.

    Article  PubMed  Google Scholar 

  53. Wolters LM, Van Buuren HR. Rosuvastatin-associated hepatitis with autoimmune features. Eur J Gastroenterol Hepatol. 2005;17:589–90.

    Article  PubMed  CAS  Google Scholar 

  54. Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani NP, Bonkovsky HL. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol. 2006;40:757–61.

    Article  PubMed  CAS  Google Scholar 

  55. Lucena MI, Kaplowitz N, Hallal H, Castiella A, García-Bengoechea M, Otazua P, Berenguer M, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol. 2011;55:820–7.

    Article  PubMed  CAS  Google Scholar 

  56. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29:412–22.

    Article  PubMed  CAS  Google Scholar 

  57. Germano V, Picchianti Diamanti A, Baccano G, Natale E, Onetti Muda A, Priori R, Valesini G. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519–20.

    Article  PubMed  CAS  Google Scholar 

  58. Adar T, Mizrahi M, Pappo O, Scheiman-Elazary A, Shibolet O. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol. 2010;44:20–2.

    Article  Google Scholar 

  59. Efe C, Purnak T, Ozaslan E, Wahlin S. Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor α agents. Hepatology. 2010;52:2246–7.

    Article  PubMed  Google Scholar 

  60. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005;42:481–9.

    Article  PubMed  Google Scholar 

  61. Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135:1924–34, 34e1–4.

    Google Scholar 

  62. Björnsson E, Talwalkar J, Treeprasertsuk S, Neuhauser M, Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010;51:2040–8.

    Article  PubMed  Google Scholar 

  63. Castiella A, Lucena MI, Zapata EM, Otazua P, Andrade RJ. Drug-induced autoimmune-like hepatitis: a diagnostic challenge. Dig Dis Sci. 2011;56:2501–2.

    Article  PubMed  Google Scholar 

  64. Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Reports. 2010;4:311.

    Article  Google Scholar 

  65. Bjornsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50:511–7.

    Article  PubMed  Google Scholar 

  66. Ohmoto K, Yamamoto S. Drug-induced liver injury associated with antinuclear antibodies. Scand J Gastroenterol. 2002;37:1345–6.

    Article  PubMed  CAS  Google Scholar 

  67. Sugimoto K, Ito T, Yamamoto N, Shiraki K. Seven cases of autoimmune hepatitis that developed after drug-induced liver injury. Hepatology. 2011;54:1892–3.

    Article  PubMed  Google Scholar 

  68. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med. 1980;92:14–9.

    Article  PubMed  CAS  Google Scholar 

  69. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312:169–72.

    Article  PubMed  CAS  Google Scholar 

  70. Bhat G, Jordan Jr J, Sokalski S, Bajaj V, Marshall R, Berkelhammer C. Minocycline-induced hepatitis with autoimmune features and neutropenia. J Clin Gastroenterol. 1998;27:74–5.

    Article  PubMed  CAS  Google Scholar 

  71. Hergue-Berlot A, Bernard-Chapert B, Diebold MD, Thiefin G. Drug-induced autoimmune-like hepatitis. A case of chronic course after drug withdrawal. Dig Dis Sci. 2011;56:2504–5.

    Article  Google Scholar 

  72. Kuhn A, Weiler-Normann C, Schramm C, Kluge S, Behne MJ, Lohse AW, Benten D. Acute liver failure following minocycline treatment—a case report and review of the literature. Z Gastroenterol. 2012;50:771–5.

    Article  PubMed  CAS  Google Scholar 

  73. Losanoff JE, Holder-Murray JM, Ahmed EB, Cochrane AB, Testa G, Millis JM. Minocycline toxicity requiring liver transplant. Dig Dis Sci. 2007;52:3242–4.

    Article  PubMed  Google Scholar 

  74. Bernal W, Ma Y, Smith HM, Portmann B, Wendon J, Vergani D. The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol. 2007;47:664–70.

    Article  PubMed  CAS  Google Scholar 

  75. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–80.

    Article  PubMed  Google Scholar 

  76. Jiménez-Alonso J, Osorio JM, Gutiérrez-Cabello F, López de la Osa A, León L, Mediavilla García JD. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Grupo Lupus Virgen de las Nieves. Arch Intern Med. 1999;23(159):1811–2.

    Article  Google Scholar 

  77. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003;12:409–12.

    Article  PubMed  CAS  Google Scholar 

  78. van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem. 2005;42:402–4.

    Article  PubMed  Google Scholar 

  79. Nakayama S, Murashima N. Overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis triggered by fluvastatin. Indian J Gastroenterol. 2011;30:97–9.

    Article  PubMed  Google Scholar 

  80. Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol. 2003;39:1095–7.

    Article  PubMed  Google Scholar 

  81. Mancini S, Amorotti E, Vecchio S, Ponz de Leon M, Roncucci L. Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med. 2010;5:193–200.

    Article  PubMed  Google Scholar 

  82. Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009;28:1001–3.

    Article  PubMed  CAS  Google Scholar 

  83. Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohn’s disease with no relapse after switching to adalimumab. BioDrugs. 2010;24 Suppl 1:25–7.

    Article  PubMed  Google Scholar 

  84. Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011;89:806–15.

    Article  PubMed  CAS  Google Scholar 

  85. Shoenfeld Y, Vilner Y, Reshef T, Klajman A, Skibin A, Kooperman O, Kennedy RC. Increased presence of common systemic lupus erythematosus (SLE) anti-DNA idiotypes (16/6 Id, 32/15 Id) is induced by procainamide. Clin Immunol. 1987;7:410–9.

    Article  CAS  Google Scholar 

  86. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 2005;52:2192–201.

    Article  PubMed  Google Scholar 

  87. Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, Brezinschek R, Tilz G, Demel U, Mueller T, et al. Blockade of tumour necrosis factor alpha significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:1224–6.

    Article  PubMed  CAS  Google Scholar 

  88. Ramakrishna J, Johnson AR, Banner BF. Long-term minocycline use for acne in healthy adolescents can cause severe autoimmune hepatitis. J Clin Gastroenterol. 2009;43:787–90.

    Article  PubMed  Google Scholar 

  89. Alfirevic A, Gonzalez-Galarza F, Bell C, Martinsson K, Platt V, Bretland G, Evely J, et al. In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. Genome Med. 2012;4:51.

    Article  PubMed  CAS  Google Scholar 

  90. Aithal GP, Daly AK. Preempting and preventing drug-induced liver injury. Nat Genet. 2010;42:650–1.

    Article  PubMed  CAS  Google Scholar 

  91. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42:711–4.

    Article  PubMed  CAS  Google Scholar 

  92. Pariente EA, Hamoud A, Goldfain D, Latrive JP, Gislon J, Cassan P, Morin T, et al. [Hepatitis caused by clometacin (Dupéran). Retrospective study of 30 cases. A model of autoimmune drug-induced hepatitis?]. Gastroenterol Clin Biol. 1989;13:769–74.

    PubMed  CAS  Google Scholar 

  93. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141:338–47.

    Article  PubMed  CAS  Google Scholar 

  94. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, Brenard R, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology. 1999;117:1181–6.

    Article  PubMed  CAS  Google Scholar 

  95. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, Shimizu S, et al. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case–control study. Pharmacogenomics J. 2008;8:29–33.

    Article  PubMed  CAS  Google Scholar 

  96. Kurosaki M, Takagi H, Mori M. HLA-A33/B44/DR6 is highly related to intrahepatic cholestasis induced by tiopronin. Dig Dis Sci. 2000;45:1103–8.

    Article  PubMed  CAS  Google Scholar 

  97. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antitubercular treatment. Am J Respir Crit Care Med. 2002;166:916–9.

    Article  PubMed  Google Scholar 

  98. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, Whittaker JC, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29:667–73.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, The National University Hospital of Iceland, 101, Reykjavik, Iceland

    Einar S. Björnsson

  2. NIHR Nottingham Digestive Diseases Biomedical Research Unit, Nottingham University Hospital NHS Trust, University of Nottingham, Nottingham, UK

    Guruprasad P. Aithal

Authors
  1. Einar S. Björnsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guruprasad P. Aithal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Einar S. Björnsson .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Allergy and Clinical Immunology, University of California School of Medicine, Davis, California, USA

    M. Eric Gershwin

  2. Medicine and Surgery, Baylor College of Medicine, Houston, Texas, USA

    John M. Vierling

  3. Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Germany

    Michael P. Manns

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Björnsson, E.S., Aithal, G.P. (2014). Immune-Mediated Drug-Induced Liver Injury. In: Gershwin, M., Vierling, J., Manns, M. (eds) Liver Immunology. Springer, Cham. https://doi.org/10.1007/978-3-319-02096-9_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-02096-9_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-02095-2

  • Online ISBN: 978-3-319-02096-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation